BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16515968)

  • 1. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
    Thompson RH; Leibovich BC; Lohse CM; Cheville JC; Zincke H; Blute ML; Frank I
    J Urol; 2007 Feb; 177(2):477-80. PubMed ID: 17222614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
    Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
    J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
    Webster WS; Lohse CM; Thompson RH; Dong H; Frigola X; Dicks DL; Sengupta S; Frank I; Leibovich BC; Blute ML; Cheville JC; Kwon ED
    Cancer; 2006 Jul; 107(1):46-53. PubMed ID: 16708355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
    Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
    Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of TNM, 2002 version, in localized renal cell carcinoma: is it able to predict different cancer-specific survival probability?
    Ficarra V; Novara G; Galfano A; Novella G; Schiavone D; Artibani W
    Urology; 2004 Jun; 63(6):1050-4. PubMed ID: 15183948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
    Frank I; Blute ML; Leibovich BC; Cheville JC; Lohse CM; Zincke H
    J Urol; 2005 Jun; 173(6):1889-92. PubMed ID: 15879769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Blute ML
    Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Giannarini G; Autorino R
    Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156
    [No Abstract]   [Full Text] [Related]  

  • 17. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
    Sengupta S; Lohse CM; Leibovich BC; Frank I; Thompson RH; Webster WS; Zincke H; Blute ML; Cheville JC; Kwon ED
    Cancer; 2005 Aug; 104(3):511-20. PubMed ID: 15973740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
    Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
    J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.